Antiva Biosciences is a biopharmaceutical company which develops therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection. The Company's platform focuses on the development and commercialization of direct-acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV and animal retroviruses.
|HQ||South San Francisco, CA, US||Map|
Antiva Biosciences total Funding
Antiva Biosciences latest funding size
Time since last funding
|3 years ago|
Antiva Biosciences investors
|Canaan Partners, Osage University Partners, Sofinnova Ventures, Hillhouse Capital Group, Brace Pharma, Brace Pharma Capital, Alexandria Venture Investments, NS Investment, Sirona Capital, Lumira Ventures, OUP (Osage University Partners), JLABS|
When was Antiva Biosciences founded?
Antiva Biosciences was founded in 2012.
Who are Antiva Biosciences key executives?
Antiva Biosciences's key executives are Gail Maderis, Steven James and Michael Cannon.
Who are Antiva Biosciences competitors?
Competitors of Antiva Biosciences include Qing Bile Therapeutics, Alkahest and Design Therapeutics.
Where is Antiva Biosciences headquarters?
Antiva Biosciences headquarters is located at 6000 Shoreline Ct, South San Francisco.
Where are Antiva Biosciences offices?
Antiva Biosciences has an office in South San Francisco.
How many offices does Antiva Biosciences have?
Antiva Biosciences has 1 office.
Receive alerts for 300+ data fields across thousands of companies